Wilmot Cancer center milestones

Technology developed by our physicians is key to vaccines against human papillomavirus, which causes nearly all cases of cervical cancer in women. The first vaccine was approved in 2006, and another vaccine is in the final stages of testing.
Wilmot physicians and scientists conduct about $15 million in grant-funded research each year.
Each year, more than 1,050 patients at the James P. Wilmot Cancer Center enroll in more than 130 local and national clinical trials testing the latest therapies.
The James P. Wilmot Cancer Center’s Stem Cell/Bone Marrow Transplant Program is New York state’s second largest, performing more than 120 transplants per year
Our 100-day-survival-rates in all categories for bone marrow and stem cell transplants exceed national benchmarks.
The Wilmot Cancer Center is an approved center of excellence for the evaluation and treatment of myelodysplastic syndrome.
The Wilmot Cancer Center was the first upstate cancer center to introduce laparoscopic prostatectomy and the first to apply robotic technology to the procedure.
Wilmot Cancer Center is home to the radiation oncology experts who were the first to take new, life-saving brain cancer treatment – shaped-beam radiosurgery -- and apply it to other patients suffering from cancer that’s spread to the lungs and other organs.
Early radiation work at the Medical Center formed the foundation for the field of Radiation Oncology.
We were among the first U.S. cancer centers to create an integrated geriatric/oncology fellowship program that teaches doctors how the unique physical, psychological and social issues that face older cancer patients shape treatment decisions.
Wilmot scientists lead a group of hundreds of researchers in 22 affiliated research sites nationwide to help develop ways to minimize or eliminate side effects of cancer treatment through a National Cancer Institute effort known as the Community Clinical Oncology Program.
Wilmot urologists and scientists have conducted some of the largest studies measuring the effectiveness of hormone therapy on men treated for prostate cancer.
Scientists at Wilmot were first to create software that improves precision when placing radioactive seeds to treat prostate cancer. The system is called Prostate Implant Planning Engine for Radiotherapy and the team is now designing a robotic system to further advance accuracy.
The Wilmot Cancer Center trains more oncologists than any other upstate New York institution.